Kymera Therapeutics, Inc. (NASDAQ: KYMR) has announced the appointment of Brian Adams, JD, as its new Chief Legal Officer and Corporate Secretary. Adams brings with him nearly two decades of leadership in the life sciences industry, with experience in corporate development, strategic planning, and governance. He will be succeeding Ellen Chiniara, who is retiring from her role.
Prior to joining Kymera, Adams served as the Chief Legal Officer of Relay Therapeutics and as the Senior Vice President, General Counsel, and Secretary at Keryx Biopharmaceuticals. He also held senior roles at Algeta ASA, AVEO Oncology, and Genzyme Corporation, as well as practiced at Bingham McCutchen LLP.
Kymera Therapeutics, a clinical-stage biotechnology company, is focused on developing targeted protein degradation (TPD) medicines for immunological diseases. The company has advanced the first degrader into the clinic and is working on building a pipeline of oral small molecule degraders to provide effective therapies for patients with these conditions.
The company's founder, President, and CEO, Nello Mainolfi, PhD, expressed excitement about the appointment, highlighting Adams' proven leadership and deep expertise as instrumental to advancing and scaling Kymera's novel programs through clinical development and toward commercialization.
Adams himself expressed enthusiasm about joining Kymera at an exciting time of progress, emphasizing his commitment to the company's long-term scientific innovation and meaningful clinical impact.
Kymera has been recognized as one of Boston's top workplaces for several years and continues to focus on transforming care for millions of patients living with immuno-inflammatory diseases through its portfolio of first-in-class oral medicines. As a result of these announcements, the company's shares have moved 4.35% on the market, and are now trading at a price of $42.46. For the full picture, make sure to review Kymera Therapeutics's 8-K report.
